NextCure (2US0) Stock Overview
A clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2US0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NextCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$16.80 |
| 52 Week Low | US$2.41 |
| Beta | 1.34 |
| 1 Month Change | 0% |
| 3 Month Change | -92.86% |
| 1 Year Change | -97.74% |
| 3 Year Change | -99.02% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2US0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.1% |
| 1Y | -97.7% | -30.9% | 13.5% |
Return vs Industry: 2US0 underperformed the German Biotechs industry which returned -30.6% over the past year.
Return vs Market: 2US0 underperformed the German Market which returned 12.4% over the past year.
Price Volatility
| 2US0 volatility | |
|---|---|
| 2US0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2US0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2US0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 43 | Michael Richman | www.nextcure.com |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.
NextCure, Inc. Fundamentals Summary
| 2US0 fundamental statistics | |
|---|---|
| Market cap | €15.32m |
| Earnings (TTM) | -€52.46m |
| Revenue (TTM) | n/a |
Is 2US0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2US0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.93m |
| Earnings | -US$60.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2US0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/11 22:29 |
| End of Day Share Price | 2025/07/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NextCure, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Alec Stranahan | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |